Advanced Urothelial Carcinoma Clinical Trial
Official title:
A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma
Verified date | January 2022 |
Source | Lee's Pharmaceutical Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection (ZKAB001) combined with Albumin-bound paclitaxel in the treatment of Advanced urothelial carcinoma
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | August 25, 2023 |
Est. primary completion date | October 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age =18 years old; - Pathologically confirmed urothelial carcinoma; - Terminal patients who have not received treatment or for the first time recurrence more than 6 months after the end of adjuvant chemotherapy after surgery; - Evaluable lesions based on RECIST V1.1; - ECOG score 0-1; - Estimated life expectancy >3 months; - The function of important organs meets the following requirements; - The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up. Exclusion Criteria: - Previously received drugs targeting PD-1, PD-L1, PD-L2 or other treatments targeting T cell costimulation or checkpoint channels; - Received systemic corticosteroid immunosuppressants 2 weeks before the study; - Suffer from active meningeal metastasis or uncontrolled, untreated brain metastasis; - Severe cardiovascular disease, such as New York Heart Association (New York Heart Association,NYHA standard) Grade 3-4 heart failure, unstable angina pectoris, unstable arrhythmia, or color heart photo indicates LVEF (left ventricular ejection fraction) < 50%; - Previous hypersensitivity to monoclonal antibodies; - The patient has known, active or suspected autoimmune diseases. The following conditions are allowed: skin diseases that do not require systemic treatment (such as vitiligo, psoriasis), type I diabetes, autoimmune hypothyroidism with hormone replacement therapy; - The study drug suffered from other active malignant tumors within 5 years before the first use of the drug. Cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, carcinoma in situ of the breast, etc., can be included in the group; - Active hepatitis B or C (unless HBV-DNA titer < 500IU/mL or copy number < 1000copies/ml, HCV-RNA negative after antiviral treatment can be included in), HIV positive or known history of acquired immunodeficiency syndrome; - Severe infection existed before screening, including but not limited to, infections requiring hospitalization, bacteremia, severe pneumonia, etc; - There has been active pulmonary tuberculosis in the past year, whether treated or not; - Live attenuated vaccine was used within 28 days prior to screening; - Patients who have previously received allogeneic bone marrow transplantation or solid organ transplantation; - Have received any other experimental drug treatment within 28 days prior to signing ICF; - Pregnant or lactating women; - Patients of childbearing age who refuse to use effective contraception; - Other researchers believe that it is not suitable to join the group. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tumor Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Lee's Pharmaceutical Limited |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose limiting toxicity (DLT) | Adverse events of level 3 or above related to the study drug occurring within 21 days after the first dose as assessed by CTCAE v5.0. | 21 days after first dose | |
Primary | Recommended phase II dose (RP2D) | DLT occurs in no more than 1/6 subjects, this dose is defined as RP2D. | 21 days after first dose | |
Secondary | objective response rate | Percentage of patients in partial and complete response | 12 months | |
Secondary | progression free survival | time between first dose of study drug to disease progression | 12 months | |
Secondary | PD-L1 expression | The positive rate of PD-L1 expression in tumor tissue. | 12 months | |
Secondary | TMB expression | The positive rate of TMB expression in tumor tissue. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00365157 -
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
|
Phase 1/Phase 2 | |
Recruiting |
NCT01487915 -
Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04064190 -
Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
|
Phase 2 | |
Not yet recruiting |
NCT06079112 -
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05544552 -
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
Active, not recruiting |
NCT02735252 -
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
|
N/A | |
Recruiting |
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05738161 -
Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma
|
Phase 1 | |
Completed |
NCT00942331 -
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
|
Phase 3 | |
Not yet recruiting |
NCT05687721 -
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04871334 -
Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma
|
Phase 1 | |
Not yet recruiting |
NCT06196736 -
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
|
Phase 3 | |
Completed |
NCT02599324 -
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04491942 -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
|
Phase 1 | |
Recruiting |
NCT05929235 -
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
|
Phase 1 | |
Recruiting |
NCT04856189 -
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
|
Phase 1/Phase 2 |